<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010017807">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACLN : Articles dans des revues avec comité de lecture non répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="bold" font="default" size="100%">Chippaux, Jean-Philippe</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Lang, J.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Amadi Eddine, S</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Fagot, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Rage, V.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Peyrieux, J.C.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Le Mener, V.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations : a field trial in Cameroon</title>
        <secondary-title>Transactions of the Royal Society of Tropical Medicine and Hygiene</secondary-title>
      </titles>
      <pages>657-662</pages>
      <keywords>
        <keyword>ESSAI CLINIQUE</keyword>
        <keyword>TRAITEMENT MEDICAL</keyword>
        <keyword>EFFICACITE</keyword>
        <keyword>VENIN</keyword>
        <keyword>SERPENT</keyword>
        <keyword>ENVENIMATION</keyword>
        <keyword>SEROTHERAPIE</keyword>
        <keyword>PROTOCOLE D'UTILISATION</keyword>
        <keyword>EFFET SECONDAIRE</keyword>
        <keyword>CAMEROUN NORD</keyword>
      </keywords>
      <dates>
        <year>1998</year>
      </dates>
      <call-num>fdi:010017807</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Transactions of the Royal Society of Tropical Medicine and Hygiene</full-title>
      </periodical>
      <isbn>0035-9203</isbn>
      <number>6</number>
      <electronic-resource-num>10.1016/S0035-9203(98)90802-1</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010017807</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_49-50/010017807.pdf</url>
        </pdf-urls>
      </urls>
      <volume>92</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>A large-scale clinical trial was conducted, according to World Health Organization Good Clinical Practice guidelines, in 7 centres in North Cameroon to determine the safety and efficacy of a polyvalent antivenom composed of purified F(ab')2. This study included 223 patients presenting clinically with an obvious snake bite, predominantly due to #Echis ocellatus$ (viper), the most abundant species in this savannah region. Clinical surveillance was maintained for 5 d in all patients and until the twenty-sixth day in 74% of cases. Two 10 mL ampoules of polyvalent F(ab')2 equine antivenom (Ipser Africa (TM)) were administered to each patient by intravenous infusion. If necessary, treatment was repeated 1 h after the end of the first infusion, and then with a frequency determined by the patient's clinical condition. Before initiation of antivenom treatment, the main clinical disorders observed on admission were oedema (93.7%) and haemorrhage (48.9%), with a clotting time longer than 30 min in 65.4% of patients. Clincal cure was obtained in 213 patients (96.8%). No amputation was necessary, and the case fatality rate was only 1.3%. On average, 4.6 (+ or - 3.7) ampoules were administered per patient ; 43% of subjects recovered after only a single infusion of 2 ampoules. Early adverse reactions, of varying degrees of severity, were observed in 6.3% of patients. A severe early reaction, anaphylactic shock, was observed in only one patient (0.4%). Serum sickness was observed in another patient. Polyvalent F(ab')2 equine antivenom given by repeated 20 mL intravenous infusions is a safe and effective treatment for envenomation caused by African vipers. (Résumé d'auteur)</abstract>
      <custom6>050MEDECI</custom6>
    </record>
  </records>
</xml>
